These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 16189945

  • 21. [Stomach evil Helicobacter pylori. A misunderstood benefactor?].
    Stiefelhagen P.
    MMW Fortschr Med; 2000 Sep 21; 142(38):4-6. PubMed ID: 11050881
    [No Abstract] [Full Text] [Related]

  • 22. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease.
    Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT.
    Gastroenterology; 2009 Nov 21; 137(5):1641-8.e1-2. PubMed ID: 19664631
    [Abstract] [Full Text] [Related]

  • 23. Helicobacter pylori and non-malignant diseases.
    Matysiak-Budnik T, Laszewicz W, Lamarque D, Chaussade S.
    Helicobacter; 2006 Oct 21; 11 Suppl 1():27-31. PubMed ID: 16925608
    [Abstract] [Full Text] [Related]

  • 24. H. pylori and peptic ulcers still misunderstood.
    Rapport RS.
    N J Med; 1999 Aug 21; 96(8):27-9. PubMed ID: 10457728
    [Abstract] [Full Text] [Related]

  • 25. Role of eradication of Cag A Helicobacter pylori in non ulcer dyspepsia.
    Babu V, Kate V, Ananthakrishnan N.
    Trop Gastroenterol; 2005 Aug 21; 26(4):211-4. PubMed ID: 16737055
    [Abstract] [Full Text] [Related]

  • 26. Whom should we "test and treat" for Helicobacter pylori?
    Ford AC, Moayyedi P.
    BMJ; 2014 May 20; 348():g3320. PubMed ID: 24846521
    [No Abstract] [Full Text] [Related]

  • 27. Maintenance therapy with H2-receptor antagonist until assessment of Helicobacter pylori eradication can reduce recurrence of peptic ulcer after successful eradication of the organism: prospective randomized controlled trial.
    Murakami K, Sato R, Okimoto T, Watanabe K, Nasu M, Kodama M, Fujioka T.
    J Gastroenterol Hepatol; 2006 Jun 20; 21(6):1048-53. PubMed ID: 16724993
    [Abstract] [Full Text] [Related]

  • 28. [Methods for increasing the efficacy and safety of Helicobacter pylori eradication regimens].
    Zakharova NV.
    Eksp Klin Gastroenterol; 2006 Jun 20; (4):59-66. PubMed ID: 17269426
    [No Abstract] [Full Text] [Related]

  • 29. Update on the role of drug therapy in non-ulcer dyspepsia.
    Talley NJ.
    Rev Gastroenterol Disord; 2003 Jun 20; 3(1):25-30. PubMed ID: 12684590
    [Abstract] [Full Text] [Related]

  • 30. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.
    Am J Med; 2005 Nov 20; 118(11):1271-8. PubMed ID: 16271912
    [Abstract] [Full Text] [Related]

  • 31. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].
    Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M, Sociedad Española de Medicina de Familia y Comunitaria.
    Gastroenterol Hepatol; 2012 Dec 20; 35(10):725.e1-38. PubMed ID: 23186826
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease.
    Jung SW, Lee SW, Hyun JJ, Kim DI, Koo JS, Yim HJ, Park JJ, Lee HS, Chun HJ, Um SH, Choi JH, Kim CD, Ryu HS.
    Dig Liver Dis; 2009 Feb 20; 41(2):134-40. PubMed ID: 18436489
    [Abstract] [Full Text] [Related]

  • 33. Helicobacter pylori as a class I carcinogen: physiopathology and management strategies.
    Vogiatzi P, Cassone M, Luzzi I, Lucchetti C, Otvos L, Giordano A.
    J Cell Biochem; 2007 Oct 01; 102(2):264-73. PubMed ID: 17486575
    [Abstract] [Full Text] [Related]

  • 34. Wiping out the bacteria that cause peptic ulcers.
    Johns Hopkins Med Lett Health After 50; 2008 Aug 01; 20(6):6. PubMed ID: 18767229
    [No Abstract] [Full Text] [Related]

  • 35. Peptic ulcer disease: clinically relevant causes and treatments.
    Mynatt RP, Davis GA, Romanelli F.
    Orthopedics; 2009 Feb 01; 32(2):104. PubMed ID: 19301796
    [Abstract] [Full Text] [Related]

  • 36. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial.
    Jarbol DE, Kragstrup J, Stovring H, Havelund T, Schaffalitzky de Muckadell OB.
    Am J Gastroenterol; 2006 Jun 01; 101(6):1200-8. PubMed ID: 16771937
    [Abstract] [Full Text] [Related]

  • 37. Pharmacotherapy of acid-peptic disorders.
    Burkard PG.
    Lippincotts Prim Care Pract; 1998 Jun 01; 2(4):398-409. PubMed ID: 9709085
    [Abstract] [Full Text] [Related]

  • 38. The health economics of Helicobacter pylori infection.
    Moayyedi P.
    Best Pract Res Clin Gastroenterol; 2007 Jun 01; 21(2):347-61. PubMed ID: 17382282
    [Abstract] [Full Text] [Related]

  • 39. Dyspepsia and Helicobacter pylori.
    Selgrad M, Kandulski A, Malfertheiner P.
    Dig Dis; 2008 Jun 01; 26(3):210-4. PubMed ID: 18463437
    [Abstract] [Full Text] [Related]

  • 40. [Comparison of the effectiveness of tri- and quadricomponent eradication therapy in patients with peptic ulcer].
    Butorov IV, Osoianu IuP, Butorov SI, Maksimov VV.
    Klin Med (Mosk); 2005 Jun 01; 83(12):50-3. PubMed ID: 16502725
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.